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Summary 
A special regulatory regime applies to products of recombinant nucleic acid modifications.  A 
ruling from the European Court of Justice has interpreted this regulatory regime in a way that 
it also applies to emerging mutagenesis techniques. Elsewhere regulatory progress is also 
ongoing. In 2015, Argentina launched a regulatory framework, followed by Chile in 2017 and 
recently Brazil and Colombia. In March 2018, the USDA announced that it will not regulate 
genome-edited plants differently if they could have also been developed through traditional 
breeding. Canada has an altogether different approach with their Plants with Novel Traits 
regulations. Australia is currently reviewing its Gene Technology Act. This article illustrates 
the deviation of the EU’s approach from the one of most of the other countries studied here. 
Whereas the EU does not implement a case-by-case approach, this approach is taken by several 
other jurisdictions. Also, the EU court ruling adheres to a process-based approach while most 
other countries have a stronger emphasis on the regulation of the resulting product. It is 
concluded that, unless a functioning identity preservation system for products of directed 
mutagenesis can be established, the deviation results in a risk of asynchronous approvals and 
disruptions in international trade. 
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Introduction 
Modern plant breeding exploits the progress in various scientific disciplines in order to increase 
the available genetic variation and to increase the precision with which the genetic material is 
managed. Genetic variation allows the development of crops with combinations of traits that 
are beneficial in one way or another. Randomly induced mutagenesis, using radiation or 
mutagenic chemicals, has for many decades enabled breeders to increase the genetic variation 
available for breeding and cherry-pick the rare beneficial mutations among the treated plant 
material (Ahloowalia & Maluszynski, 2001). Since the 1970s, recombinant nucleic acid 
technology provided breeders with access to the genetic material of basically any organism – 
a huge breakthrough in terms of available genetic variation. However, the potential of 
recombinant nucleic acid technology also prompted discussions around the biosafety of this 
very potent technology (Berg et al., 1974) and the first regulatory frameworks were developed 
for these so-called genetically modified organisms (GMOs). 
In recent years, genome editing techniques have also been developed that enable directed (or 
targeted) mutagenesis yielding beneficial mutations without the mutational load of randomly 
induced mutagenesis. These techniques for directed mutagenesis include (inter alia) site-
directed nuclease systems such as clustered regularly interspaced short palindromic repeats 
(CRISPR) together with a Cas (CRISPR associated) endonuclease protein, zinc finger 
nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases 
and the nucleic acid-based oligonucleotide-directed mutagenesis (ODM). It is beyond the 
scope of this review to describe the genome editing techniques in detail or the various genetic 
alterations that these enable, however several recent reviews are available on various aspects, 
such as the technical details (NTWG 2012, Chen and Gao 2014, Abdallah et al. 2016, Hilscher 
et al 2017, HLG SAM 2017), specifically on CRISPR systems (Bortesi and Fischer 2015, Ding 
et al. 2016, Paul III and Qi 2016, Samanta et al. 2016, Stella and Montoya 2016, Arora and 
Narula 2017, Volpi e Silva and Patron 2017, Yin et al. 2017), applications in plants (Brinegar 
et al. 2017, Hilscher et al 2017, Ricroch et al. 2017, Zhang et al. 2017), as well as the historical 
development (Songstad et al. 2017) and comparisons with other breeding techniques (Georges 
and Ray 2017). 
The current GMO legislation in the European Union (EU), centers around Directive 2001/18 
(the release directive) and Regulations 1829/2003 and 1830/2003. One of their regulatory 
approaches consists of an pre-market authorization regime for GMOs, which are subject to an 
environmental and human health risk assessment. After authorization, GMOs are subject to 
traceability, labelling, monitoring and liability obligations. In Art. 2(2) of the release directive, 
a GMO is defined as “an organism in which the genetic material has been altered in a way that 
does not occur naturally by mating and/or natural recombination”. As some precision breeding 
techniques mimic naturally occurring processes one could argue that these techniques would 
already not be considered GMOs according to this definition. However, Art. 3(1) in connection 
with Annex 1B of the EU release directive exempts ‘mutagenesis’ from the definition. 
According to some views, such an exemption would not have been needed if such techniques 
would not have been covered by the GMO definition in the first place (See Poortvliet et al, 
2018, discussing the various options of the legal categorization). Mutagenesis is a technology 
that yields genetic alterations mimicking natural, spontaneous mutations, albeit through 
processes that are generally considered the result of human intervention. Hence, mutagenesis 
is considered a GM technique under EU law. For several years though, it was not clear what 
kind of mutagenesis techniques would be covered by the exemption. The reason for doubt was 
especially the wording of recital 17, which states that “(t)his Directive should not apply to 
organisms obtained through certain techniques of genetic modification which have 
conventionally been used in a number of applications and have a long safety record.” This 
wording gave rise to concern whether new mutagenesis techniques, particularly directed 
mutagenesis, would also be covered by the exemption. For a technical analysis of which genetic 
alterations fall under the mutagenesis exemption, we recommend Wasmer and Robienski 
(2018). 
Whether precision breeding techniques, such as directed mutagenesis, are subject to the 
provision of the release directive has been subject to debate in the literature. (Eriksson, 2018; 
Hartung & Schiemann, 2014; Jansson, 2018; Krämer, 2015, Sprink et al., 2016; Spranger, 
2015). Legal scholars have pointed out the fact that there is a difference between the legal 
requirements regarding the scope and the exemption in the release directive (Spranger, 2015). 
In particular, it was under question whether the mutagenesis exemption should be interpreted 
strictly in the sense given to the word mutagenesis at the time of adoption of the release 
directive in 2001 (Spranger, 2015) or whether it also covers mutagenesis techniques developed 
after 2001 (AG Bobek, 2018). Should Annex IB of the directive be interpreted in a historical 
way (i.e. what the lawmaker intended in the time of writing) or in an evolutionary way taking 
into account also developments since that time (i.e. what the lawmaker would have regulated 
in case it would have implemented the provisions today?). This resembles a methodological 
question in law, namely where to draw the line between interpretation (the responsibility of the 
Court) and law-making (the responsibility of policymakers) (Purnhagen & Rebasti, 2007). 
In this article, we analyze a recent ruling from the Court of Justice of the European Union 
(CJEU) on mutagenesis and the scope of the release directive, and discuss its consequences. 
We compare the EU approach to directed mutagenesis, incl. the CJEU ruling, with the approach 
taken by several other jurisdictions and discuss the implications for international trade when 
there is discrepancy among the approaches. We also point to some potential steps forward for 
EU policy makers. 
 
The EU court case on mutagenesis 
A judgment from the Court of Justice of the European Union (CJEU) concerning the 
interpretation of Articles 2 and 3, and of Annexes 1A and 1B, of the release directive (CJEU, 
2018) provides an indication to how EU will apply existing legislation to directed mutagenesis 
under its current regime. The case was initiated when the French Conseil d´État (Council of 
State) on 3 October 2016 requested a preliminary ruling from CJEU following complaints from 
nine French organisations that the French government refused to ban the cultivation and 
marketing of herbicide-tolerant oilseed rape varieties obtained by randomly induced, or other 
types of, mutagenesis. 
The CJEU Advocate General (AG) delivered first an Opinion on 18 January 2018 (AG Bobek, 
2018). In this Opinion, the AG first highlighted that products derived from mutagenesis are in 
principal covered by the definition of a GMO (AG Bobek, 2018, paragraph 60). Otherwise one 
would not need to exempt mutagenesis from the definition (AG Bobek, 2018, paragraph 62). 
With regards to the interpretation of the exemption, the AG rejected the historical interpretation 
for the benefit of an evolutionary interpretation, which opens up the possibility to include 
directed mutagenesis techniques into the exemption via interpretation (AG Bobek, 2018, 
paragraph 110). To come to this conclusion, AG Bobek ironically uses an argument from 
historical interpretation: it is unlikely that the drafters of the directive did not account for 
potential technological process (AG Bobek, 2018, paragraph 77). In the eyes of the AG this 
solution does not result in the fact that directed mutagenesis techniques will remain 
unregulated. Rather, he invites the EU institutions or Member State policymakers to provide 
clearer and more detailed regulations within the existing general regulatory regimes for trade 
in goods, foods and seed law. If neither of the two picks up the ball, however, he sees potential 
tensions with the precautionary principle (AG Bobek, 2018, paragraph 122). Following the 
AG’s solution, the majority of directed mutagenesis techniques are exempted from the release 
directive but can be regulated at the member state level. However, Member State or EU-wide 
initiated legislation will be under scrutiny of EU primary law, in particular the freedom of 
goods in Art. 34 TFEU. Even if member states or the European Commission (EC) do not initiate 
additional legislation, plants derived by mutagenesis would be regulated under the EU seed 
law. If national regulation would concern directed mutagenesis in foods and feed, in addition 
the EU legal regime regarding food and feed law would be applicable (Purnhagen et al., 2018a). 
The CJEU delivered its judgment on 25 July 2018. Contrary to the AG, the Court followed a 
historical interpretation. Whereas it was confirmed that mutagenesis techniques are considered 
GMOs (CJEU, 2018, paragraph 30), and that these under certain conditions are excluded from 
the scope of the directive (CJEU, 2018, paragraph 37 and 40), the Court relied strictly on 
Recitals 4, 5 and (in particular) 17 of the release directive which states that the exemption is 
applicable to those GM techniques which have been conventionally used in a number of 
applications and have a long safety record (CJEU, 2018, paragraph 45). Whereas the court also 
acknowledges that the release directive does not provide any definition of the techniques to be 
excluded (CJEU, 2018, paragraph 43), it is also taken into consideration that the case includes 
techniques of directed mutagenesis involving the use of genetic engineering which have been 
developed since the release directive was adopted in 2001 and for which the risks have not 
been established with certainty (CJEU, 2018, paragraph 47). This interpretation, which would 
subject the products of directed mutagenesis to the provisions of the release directive, thus 
implies that the two “subcategories” of randomly induced mutagenesis and directed 
mutagenesis are sufficiently distinct to warrant differential treatment under the release 
directive. The CJEU also does not take into account that many products of directed mutagenesis 
would be indistinguishable from those resulting from natural, spontaneous mutations (thus not 
altered in a way that does not occur naturally) (for the impact on the EU regulation of this lack 
of consideration, see Purnhagen et al., 2018b) and instead adopts a more process-based 
interpretation resulting in these products being classified as GMOs in the first place based on 
the use of recombinant nucleic acids in the process. In conclusion, this judgment (which cannot 
be appealed) indicates that the EU may subject the products of directed mutagenesis to the 
provisions of the release directive and the ones referring to it (Purnhagen et al., 2018a). 
 
The approach to directed mutagenesis in other jurisdictions 
It is important to see the EU approach to directed mutagenesis in an international context as 
other countries, particularly on the American continents, have already developed, or are in the 
process of developing, a regulatory procedure for handling the products of New Breeding 
Techniques (NBTs) including directed mutagenesis. We will here describe the approach taken 
by Argentina, Brazil, Chile and Colombia in South America, Canada and the United States in 
North America, and Australia, and then continue with a comparative analysis to the EU 
approach. 
Argentina 
Argentina was one of the first countries in Latin America to implement a system to evaluate 
the biosafety of GMOs for agriculture use. Argentina also recognized early the value of NBTs 
for crop R&D (Whelan & Lema, 2015). CONABIA decided to work with the definitions of 
GMO and of biotechnology contained in the Cartagena Protocol on Biosafety to the Convention 
on Biological Diversity (CBD), and include these in Resolution 701/11 that regulates activities 
with GMOs for agricultural use. CONABIA applies different criteria to determine if a product 
derived from NBT should be considered GMO or not. The first consideration is that products 
obtained through any NBT must be submitted to a prior consultation. The second one is the 
scope of genetic change; a novel combination of genetic material is the insertion into the 
genome of genes or DNA sequences that are a part of a genetic construct. From these criteria 
and after two years of debate, Resolution 173/15 was adopted presenting a procedure to 
determine if a product obtained using NBTs is covered or not by Resolution 701/11. Specific 
features to highlight in this resolution are: 1) Its analysis is based on a case by case logic, 2) It 
is not restricted to a list of NBTs, 3) If the product is still at the design stage, the developer can 
consult the committee about the status of the hypothetical product, and 4) The Biosafety 
Committee must perform the assessment within 60 days. This procedure is outlined in Figure 
1 and described hereafter. During the early consultation procedure, the Biosafety Committee 
analyses if there is a new combination of genetic material in the genome. In affirmative cases, 
the product is considered a GMO and the applicant is notified that the product will be subject 
to the corresponding regulatory procedures. In negative cases, the committee analyses if the 
development of the NBT product uses a transgene temporally. If it does, and the final product 
is not free of transgene, it is considered a GM. If the product does not contain a new 
combination of genetic material in the genome generated by the use of these techniques, the 
applicant will be notified that the product does not fall under the GMO Resolution and the 
plants will be treated as conventionally bred varieties. In order to initiate the consultation, the 
information that the applicants shall submit is the following: 1) the breeding methodology used 
to obtain and select the crop, 2) the new trait or characteristic introduced, 3) the evidence of 
the genetic changes present in the final product, 4) the phenotypic characterization, and 5) the 
evidence of removal of the temporary transgene used to obtain the product (if applicable). The 
Biotechnology Directorate and CONABIA may request the applicants to file additional data 
and information in order to complete their assessments. A similar procedure applies to 
hypothetical products. Only a few cases have hitherto been presented for consultation. These 
include annual crops as well as ornamental plants and fruit trees. The main traits are herbicide 
resistance, high oleic acid content and modifications for consumers and industries. Some of the 
cases presented to the commission were non-browning potatoes with an edited polyphenol 
oxidase gene, developed by INTA (http://intainforma.inta.gov.ar/?p=42900), and herbicide-
tolerant soybean developed by the company Bioheuris. Three cases of genome-edited animals 
have also been presented (https://www.lanacion.com.ar/2150187-una-firma-de-rosario-
desarrolla-cultivos-resistentes-a-herbicidas-con-edicion-genica). 
Australia 
Australia is operating under the regulatory framework legislated in 2001, referred to as The 
Gene Technology Act 2001. This Act provides a working framework for research, field trials 
and commercial release of GMOs. In parallel, Food Standards Australia New Zealand 
(FSANZ) assesses applications for approval for food derived from GMOs. Currently, nearly 
all cotton grown in Australia is GM and in 2017 there was 491,528 hectares of GM canola. In 
addition to the national legislation that provides this working framework the State and Territory 
Governments have the ability to restrict the release of GMOs. As a consequence, while most 
states permit the commercial cultivation of approved GMOs some do not. The Gene 
Technology Regulator initiated a review of the Act to provide clarity about whether organisms 
developed with new technologies are subject to regulation as genetically modified organisms 
(GMOs) and to ensure that they are regulated in a manner commensurate with risk. 
Submissions were sought late 2017 to early 2018 from the public and stakeholders on proposed 
amendments, with the issues raised in the submissions being currently under consideration. 
The next step will be for proposed amendments to be provided to the Commonwealth and State 
and Territory governments. Any amendments would need to be legislated by the Parliament. 
The key proposals covered a range of regulatory frameworks with “option 3” being viewed as 
best supporting the effectiveness of the legislative framework at this time. For this option 
organisms modified using site-directed nucleases without templates to guide genome repair 
(i.e. SDN-1) would not be regulated as GMOs. Currently, if a template is used to guide genome 
repair (i.e. SDN-2 and SDN-3), the resulting organisms are GMOs, as are organisms modified 
using oligonucleotide-directed mutagenesis. This is argued to be based on an assessment of 
risk, compliance enforceability and consideration of the policy settings of the regulatory 
scheme. With respect to RNAi the proposal is that applying RNAs to temporarily induce RNAi 
are techniques that are not gene technology providing there are no changes to genomic 
sequences. A further consideration for the uptake of new breeding technologies in Australia 
will be the decisions of its major export partners, as the majority of its major crops, such as 
wheat, are exported. For example, even if Australia does not regulate a specific new breeding 
technology but its major markets for the resulting agricultural product do, that would have 
substantive consequences that need to be assessed by the relevant industry and stakeholders. 
Brazil 
The current Biosafety Law in Brazil was adopted in 2005 (CTNBio, 2005). The law gives the 
mandate to the Brazilian National Biosafety Technical Commission (CTNBio) to evaluate how 
new technologies might impact biosafety for the environment and human/animal health in 
Brazil and then, if necessary, to propose legislation regarding these new technologies. When 
the law was created, most of the NBTs were at its infancy, so they were not really considered 
at that time. Thus, in 2014 the CTNBio created a working group of experts that studied these 
new breeding techniques such as gene editing for three years, aiming to propose a more updated 
normative. The CTNBio´s Normative Resolution No16 (RN16), published on January 15th 
2018, under the scope of the Brazilian Biosafety Law, was approved by unanimous vote among 
CTNBio´s 27 members (CTNBio, 2018). The normative, which is also based on other 
countries’ experiences, evaluates in a case-by-case consultation system if a product generated 
by the NBTs will be considered a conventional or a transgenic organism. Under the RN16 
consultation procedure developers provide information on the product, including the methods 
used to generate it. The absence of recombinant DNA/RNA in the progeny, the presence of 
genetic elements that could be obtained by conventional breeding; the presence of induced 
mutations that could also be obtained by older techniques, such as radiation or chemical 
mutagenesis, or even the presence of induced mutations that could occur naturally, are in a 
case-by-case analysis considered conventional organisms/products in many situations. In June 
2018 the CTNBio evaluated, under the scope of RN16, the first genome edited organism in 
Brazil submitted to analysis. A Saccharomyces cerevisiae strain received mutations present in 
four genes from another S. cerevisiae strain by the use of a CRISPR/Cas9 strategy where only 
the mutations remain present in the final product. The genome edited organism, developed to 
improve alcohol production from sugarcane, was considered a conventional yeast since these 
mutations could be obtained by classical breeding or other older mutagenesis induction 
techniques, but with much less precision. A genome-edited hornless cow has now also been 
decided for regulation as a conventional organism, as well as a second genome-edited yeast 
strain, and in the end of November a vote on genome-edited waxy maize will take place. 
Canada 
Canada regulates based on the product but has a regulatory system that is unique among 
industrial countries, in that it regulates plants with novel traits (PNTs), regardless of the method 
used to develop them. A plant developed by chemical or radiation mutagenesis can be treated 
as a conventional variety and subject to agronomic and safety requirements, whereas a plant 
developed by transgenic breeding will always be treated as a PNT. However, a plant developed 
by mutagenesis technologies can also be treated as a PNT if the trait that is being focused on 
is viewed to be outside a normal band of expression. Canadian plant breeders perceive that if a 
gene is modified to express higher or lower by either 30% or more, then it will be treated as a 
PNT, regardless of the process. There is evidence emerging that public sector breeders are 
taking steps in their breeding programs to scale back varieties that have traits expressing 
beyond the 30% self-assessed benchmark. Canada has approved two herbicide tolerant genome 
edited canola varieties, one in 2013 developed by ODM technology and the other in 2014 by 
site-directed mutagenesis (CFIA, 2013; 2014). Canada’s use of the PNT regulatory trigger 
creates some challenges when it comes to the use of genome editing. Since the first GM canola 
varieties were approved for production in Canada in 1995, all GM varieties have been regulated 
as PNTs. This creates problems for public plant breeders, particularly because many 
commodity importers view PNT status as being the equivalent of GM status. For example, 
some universities have decided that no PNT variety research will be undertaken as to do this, 
dedicated, parallel systems would be required. Duplicating laboratories, phytotrons, 
greenhouses and field trials are expenses beyond the scope for public breeding programs. If 
genome editing regulations are treated as PNTs, this will most likely prohibit public sector 
plant breeders from using these technologies. However, the fact that the USA is treating 
CRISPR-Cas9 as conventional plant breeding will put pressure on Canadian regulatory 
agencies to ensure there is regulatory harmonization between both countries regarding genome 
editing regulation. 
Chile 
The Chilean legal framework regarding GM plants has been well described by Sánchez & León 
(2016). The Exent Resolution 1523/2001 establishes procedures for import, domestic 
propagation, and re-export of propagated GM plant material. National research and 
development (R&D) activities are subject to the provisions of the Resolution, including 
contained use to experimental field release and surveillance and a species-specific biosafety 
protocol (Sánchez, 2015). Hence, the regulatory framework 1523/2001 allows GM seed 
production exclusively for export and R&D activities, yet those seeds are not allowed to remain 
in the country or be locally commercialized. From the GM food/feed perspective, some rules 
have been issued by the Health Ministry in order to analyze, on a case-by-case basis, the 
approval for commercialization in Chile. However, they are not yet in place and there are not 
now restrictions on imports of GM products categorized as food or feed. Chile began discussing 
NBTs in 2016, as a result of a growing interest by several South American governments in 
these advances in plant biotechnology. A working table was initiated involving different 
governmental agencies of the Agriculture Ministry. Considering that NBTs represent an 
important advance and potential for national activities, including commerce and R&D, the 
working group published in July 2017 general procedures for a case-by-case analysis. In 
general terms, the Chilean effort has focused on developing analytical procedures by which the 
1523/2001 resolution could apply to the materials derived from new technology. From the 
analysis, if these materials are considered not subject of the normative, they should be excluded 
from the GM regulations and released as conventionally bred plants. The case-by-case analysis 
of NBT-derived products is carried out by the Forestry and Agricultural Protection Division of 
the Agricultural and Livestock Service (SAG). This analysis is centered on the question if a 
“new combination” of genetic material has occurred. The most recent understanding of “new 
combination” is the stable insertion of DNA fragments or coding sequences leading to gene 
products (proteins), elements of the RNA interference process, double strand RNA, or other 
sequences including information for signal peptides and/or regulatory elements. The 
categorization as lacking a “new combination” enables the developer (or representative) to start 
regular production in Chile. A consultation form is regularly used by the Protection Division 
of SAG. The first section covers aspects of the new material’s individualization intended to be 
introduced to the environment (i.e. species, variety/line, phenotype description, and developer 
antecedents). The second section covers the process used in the development and 
characteristics of the technique used in the development of the individual plant and modified 
DNA sequences. A technical scheme for the procedure/technique (breeding pipeline) is 
required. The third section addresses information about previous releases and permissions in 
third countries. 
Colombia 
The Colombian Agricultural & Farming Institute (ICA) is responsible for exerting technical 
control over production and commercialization of agricultural and farming feedstock, animal 
genetic material and seed for sowing, with the purpose to prevent risks that may affect 
agricultural and farming health, food safety and domestic agricultural and farming production. 
Recently, ICA made official the Resolution No. 00029299 (https://diario-
oficial.vlex.com.co/vid/resoluci-n-n-mero-
736329965?_ga=2.121199179.279196541.1534802394-1753836802.1534802394). This 
Resolution sets forth the procedure that must be applied to crops obtained by means of using 
phytoimprovement innovation techniques through modern biotechnology where the final 
product does not contain any foreign genetic material, in order to determine if it is a Living 
Modified Organism (LMO) or not and consequently decide whether the regulations on LMOs 
shall be applied or not. 
USA 
In 1986, the Office of Science and Technology Policy (OSTP) developed a Coordinated 
Framework for the Regulation of Biotechnology (OSTP, 1986). Using existing legal 
authorities, OSTP assigned three agencies – Animal Plant Health Inspection Service (APHIS), 
Environmental Protection Agency (EPA), and Food Drug Administration (FDA) – distinct 
regulatory tasks. APHIS used Plant Protection Act to regulate for plant pests and noxious 
weeds. EPA used Federal Insecticide Fungicide Rodenticide Act to regulate crops intended to 
control insects (plant-incorporated pesticides) and Toxic Substances Control Act to regulate 
microbes as “new chemicals.” FDA used Federal Food Drug & Cosmetic Act to create a 
voluntary consultation process for food or feed coming from biotechnology and, in 2009, the 
same act to regulate DNA constructs in genetically-engineered animals as new veterinary 
drugs. For APHIS and FDA, regulatory approvals must comply with National Environmental 
Policy Act, meaning preparation of an environmental assessment or, the more detailed, 
environmental impact statement prior to an approval. As the EPA approval process is an 
equivalent evaluation, EPA does not have a separate NEPA obligation. Regarding genome-
editing techniques, the question arises: how will these regulatory agencies respond to NBTs? 
APHIS has responded with an “Am I Regulated?” website (USDA, 2018a). From February 
2017 through July 2018, APHIS responded to twenty-two inquiries and indicated that many 
using NBTs were not subject to APHIS regulation as plant pests or noxious weeds (USDA, 
2017a; 2017b). Building on these “not regulated” determinations, the Secretary of Agriculture 
in March 2018 issued a statement that “USDA does not regulate or have plans to regulate plants 
that could otherwise have been developed through traditional breeding techniques as long as 
they are not plant pests or developed using plant pests.” (USDA, 2018b) The Secretary 
referenced genome editing as falling outside APHIS regulation. Farmers in the United States 
are growing genome-edited crops such as herbicide-resistant canola containing a one-letter 
change in the genetic code. This canola is the product of a mega-nuclease breeding technique. 
The EPA stated that “the degree of editing … does not necessarily influence the pesticidal 
nature of the product” and that “knockouts could still be considered as plant-incorporated 
protectants” depending on the … intent of the product such as disease resistance.” (EPA, 
2018a) EPA intends to govern NBTs having impacts on plant diseases and insects. In June 
2017, EPA approved an RNAi maize with a modification to control corn rootworm. EPA also 
uses its pesticide regulations to oversee mosquitoes modified through various types of sterile 
insect technology (EPA, 2018b). The FDA has not declared a regulatory stance regarding foods 
or feeds derived from NBTs. A best guess is that FDA will apply voluntary consultation in a 
manner similar to the voluntary consultation for food and feed from rDNA crops. In proposed 
regulations (FDA, 2017), FDA asserted regulatory control over NBT animals, such as the 
TALENS hornless dairy cattle, as veterinary drugs. After criticism, FDA placed these proposed 
regulations on hold. Whether FDA will regulate NBT animals is undetermined as of July 2018. 
USDA-Agricultural Marketing Service has the task of adopting labels for bioengineered foods 
(USDA, 2018c). The Agricultural Marketing Service of USDA (AMS) has not decided whether 
NBTs create “bioengineered” foods, as defined in the statue, and will likely not reach a decision 
until December 2018. 
 
The EU court mutagenesis ruling in an international context 
A comparison to the approach of other jurisdictions 
A striking similarity between the approaches taken hitherto by the countries on the American 
continents included in this study is the adherence to a case-by-case procedure to determine the 
regulatory status of a product developed by any NBT. Any similar case-by-case procedure is 
currently not explicitly expressed in EU legislation nor acknowledged by the CJEU 
mutagenesis ruling. A large coalition of organisations and associations has recently called upon 
the EC to identify an authority which would be capable of verifying individual cases for 
conformity with inclusions, exclusions or exemptions under the current GMO regulatory 
framework (European Initiative for Genome Editing in Plants, 2018). This would be a first 
prerequisite to implement a case-by-case approach for status determination, followed by 
establishing once and for all exactly what a GMO is according to the definition contained in 
the release directive. Though giving certain indications, the CJEU mutagenesis ruling does not 
in fact provide any conclusive and definite interpretation of the GMO definition. A way 
forward is either to agree on a common interpretation, or to amend the release directive in order 
to provide an unambiguous definition (Eriksson et al., 2018). Regarding the definition of a 
GMO, many of the American countries take a similar stance. Argentina and Chile emphasize 
that a new combination of genetic material, stably inherited, is required for the product to fall 
under the GMO regulation, and Brazil states that products not containing recombinant nucleic 
acids are regulated as conventional products. Colombia seems to be adopting a similar 
approach. Brazil also emphasizes that products containing genetic elements that could have 
been obtained by conventional breeding are to be regulated as conventional products, similar 
to the approach by USDA. Canada´s approach is, as already explained, altogether different; 
however, there is an ambition to harmonize the regulations of NBTs particularly with the US. 
Australia, following the recent consultation, may decide to take a middle way where SDN-2, 
SDN-3 and ODM applications would be regulated as GMO, but SDN-1 applications not. 
However, the need for export-friendly regulations is also acknowledged. All of this is, in part 
or fully, in contrast to the CJEU ruling, which has an inclination towards a process-based 
interpretation of GMO in the context of mutagenesis. In the ruling, it is said that “since […] 
certain of those techniques/methods involve the use of chemical or physical mutagenous agents, 
and others involve the use of genetic engineering, those techniques/methods alter the genetic 
material of an organism in a way that does not occur naturally” (CJEU, 2018, paragraph 29) 
and “It follows that organisms obtained by means of techniques/methods of mutagenesis must 
be considered to be GMOs within the meaning of Article 2(2) of Directive 2001/18” (CJEU, 
2018, paragraph 30). This would imply that the EU GMO regulatory framework does not 
explicitly acknowledge that the certain products of mutagenesis may be highly similar, or even 
identical, to the products of conventional breeding. There is therefore a high probability that 
the EU will treat, given the current legislation, the products of directed mutagenesis differently 
than many of its important trading partners around the world. 
Trade with agricultural commodities 
The ruling of the CJEU can result in significant trade disruptions. Products derived from crops 
that are subject to the EU GMO release directive and regulations referring to it are not allowed 
for import into the EU until they have been submitted for approval for import and processing. 
Further, in most cases these products need to be labelled as GMOs. The problem is that many 
of the products of directed mutagenesis are technically very challenging and costly to trace. 
Also, even with a manageable traceability system in place, it would not be possible to correctly 
identify the origin of many products, i.e. it will not be possible to provide evidence to which 
method has been used to develop the product. As these products might not be detectable, they 
are credence goods and require functioning identity preservation systems (IPS) similar to 
organic products (Purnhagen et al, 2018). There is however one important distinction to organic 
products (McCluskey et al., 2018). While the appearance of organic products in non-organic 
products does not matter, the appearance of GMOs in non-GMO products matters (Venus et 
al., 2018). As long as traders are not able to provide convincing IPS systems, international trade 
can easily be blocked (Wesseler and Kalaitzandonakes, 2011). The EU imports about 32.5 
million tons of soybean and soybean meal, mainly from Argentina, Brazil, and the US and 
about 5 million tons of rapeseed and rapeseed oil mainly from Australia, Canada, and the 
Ukraine. These are the markets that might soon be affected by the ruling as soybeans are in the 
pipeline (Table 1) and two oilseed rape varieties (canola) have reached the market in Canada 
and the US (Table 2). The ruling may also expose the seed companies to potential liability 
issues in case export restrictions caused by asynchronous approval as illustrated by the court 
case against Syngenta for lost export markets due to the introduction of an insect resistant corn 
variety in the US but not yet approved in China (Hadden Farms Inc. v. Syngenta Corp., 2014). 
Important to mention is also that China is an emerging big player internationally for genome 
edited crops. Being completely dominant when it comes to CRISPR/Cas and other patent 
applications, China is through heavy governmental investments gaining considerable 
experience with genome editing applications in rice and may sooner or later move into also 
many other crops (Bosma, 2018). Japan is also moving ahead with a policy on genome editing, 
with a governmental panel very recently announcing that the regulations governing products 
of genetic recombination will not apply to products in which mutations are produced at a 
targeted site without new genes inserted (NHK World – Japan, 2018). Apart from already 
existing commercial applications, there are also a large number of research applications on 
various crops and traits for which directed mutagenesis/genome editing tools have been applied 
(Schaart et al., 2016; Subburaj et al., 2016; Ricroch et al., 2017; Zhang et al., 2017; Bogdanove 
et al., 2018), not the least in Europe. It is therefore likely that many more commercial 
applications will reach the international market in the near future; if not developed in Europe, 
then elsewhere. This may result, independent of the country, in asynchronicity in approval and 
further may result in trade disruptions not only between the EU and its trading partners but also 
among other countries as mentioned above. IPS have been introduced for credence goods in 
food value chains with similar problems such as for organic agriculture or non-GM labelled 
food products (Castellari et al., 2018). Such kind of IPS may offer a solution (Venus et al., 
2018) but increase costs (Kalaitzandonakes et al., 2018) that may be substantial depending on 
country regulations (Bovay and Alston, 2018). Harmonization of approval processes at 
international level might be required to avoid substantial trade disruptions (Wesseler and 
Kalaitzandonakes, 2011). A recent (30 Oct 2018) statement on agricultural applications of 
precision biotechnology that was presented by Argentina and now supported by several 
countries (Argentina, Australia, Brazil, Canada, Colombia, Dominican Republic, Guatemala, 
Honduras, Jordan, Paraguay, Uruguay, USA and Vietnam, as well as the Secretariat of the 
Economic Community of West African States) in the World Trade Organisation (WTO) 
Committee on Sanitary and Phytosanitary Measures mentioned, amongst other things, that 
“Given the differences internationally in approaches used to assess agricultural biotechnology, 
due consideration should be exercised by governments to avoid arbitrary and unjustifiable 
distinctions between end products derived from precision biotechnology and similar end 
products obtained through other production methods” and “Cooperative work by governments 
to minimize unnecessary barriers to trade related to the regulatory oversight of products of 
precision biotechnology, including the exploring of opportunities for regulatory and policy 
alignment, should be pursued where possible” (WTO, 2018). This is a clear signal that the EU 
expeditiously needs to look over the scope of the release directive in order to align with many 
of the important trading partners, as the opposite can hardly be expected (i.e. that all the other 
countries decide to follow EU´s approach). 
Reactions from the European seed sector 
It was not surprising that the reactions from the European seed sector to the CJEU ruling were 
highly negative. The European Seed Association (ESA) declared already the same day that 
they see the ruling as a missed opportunity for agricultural innovation in the EU, indicating 
also the risk that the EU remains isolated from the rest of the world with respect to innovative 
agricultural developments (ESA, 2018). Some of the major seed companies also announced 
that they most likely will look for other markets than the European for products developed with 
genome editing. BASF expressed that the ruling will not affect the company much since it is 
run on a global platform, however that those who should worry are the European citizens who 
will not enjoy the benefits. Bayer, that recently purchased Monsanto, also ruled out trying to 
develop genome edited crops for the European market, and a comment from Syngenta was 
equally discouraged (Reuters, 2018). A press release from EuropaBio also raised concerns that 
the EU could miss out on the benefits of genome editing. The comment from Secretary General 
John Brennan was somewhat more cautious, saying that the necessary regulatory clarity is still 
lacking and that the EU and its member states now need to engage in public dialogue with their 
citizens about genome editing (EuropaBio, 2018). Among supporters of organic agriculture, a 
discussion about the potential of genome editing for addressing solutions has started and this 
might have an impact on policy makers (Shao et al., 2018). We agree and would add that one 
detail to start with is a new Eurobarometer specifically on the topic of genome editing, which 
would be of great help for the EC and the European Parliament (EP) to properly address the 
issues related to governance of precision breeding. 
The aftermath of the EU court ruling – has the final word been said? 
As mentioned earlier, the EU court ruling on mutagenesis indicates that the EU will subject the 
products of directed mutagenesis to the provisions of the release directive and the ones referring 
to it. However, there are some complicating factors that are currently being raised at various 
levels. First, neither the release directive nor the court ruling offer any tangible definition of 
mutagenesis. It is also a fact that some national jurisdictions within the EU approach 
conventional mutagenesis differently, with e.g. France in their national implementation of the 
release directive aligns with the GMO definition embodied in the Cartagena protocol in the 
sense that randomly induced mutagenesis is not considered to be GMO at all. This may have 
huge implications, also considering that some EU member states (such as Sweden) in their 
written observations to CJEU on case C-528/16 argued that the organisms resulting from 
directed mutagenesis should not be considered GMOs at all. It is therefore important that the 
EU takes action to provide a functional definition of mutagenesis, and in the process actively 
seeks advice from the scientific community. 
Sweden also voiced some serious concerns in a letter to the EC on 1 October 2018, asking the 
EC to clarify the issues related to detection of plants and products resulting from new 
mutagenesis methods, to clarify the conditions within recital 17 of the release directive (which 
exempt from the directive GMOs which have conventionally been used in a number of 
applications and have a long safety record), and also questioning the logic in subjecting two 
organisms that carry exactly the same molecular changes to different risk assessment 
procedures. The letter also urged the EC to analyse the consequences of the CJEU ruling in 
relation to the WTO agreements (Swedish Board of Agriculture, 2018). 
The potential problem for international trade has also been emphasized in a recent (13 Nov 
2018) statement from the Chief Scientific Advisors to the European Commission (EC), which 
listed a number of issues and questions arising from the court ruling, such as the GMO 
definition, safety considerations, detection and identification issues, as well as some potential 
consequences. Amongst others, it is explained that application of the obligations of the GMO 
regulations to the products of genome editing, such as traceability and labelling, will be 
difficult to implement, and this problem will be exacerbated when exporting countries start to 
market varieties and products that are not regulated within their own jurisdictions (European 
Commission, 2018). 
 
Conclusions 
The negative reactions from the EU seed sector, as well as from many scientists (IPMB, 2018; 
EPSO, 2018), to the CJEU ruling on mutagenesis are understandable. We nevertheless here 
aim at providing some openings for a constructive way forward. Irrespective of the slightly 
problematic issue that the CJEU engaged in scientific speculation in the ruling (CJEU, 2018, 
paragraph 48), it is nevertheless encouraging that the ruling considers that direct modification 
of the genetic material through mutagenesis makes it possible to obtain the same effects (in 
terms of risk) as the introduction of a foreign gene. This statement makes it possible to address 
the issues of “conventional use in a number of applications” and “long safety record”, as it can 
be reasonably argued that the type of products resulting from transgenesis that have had 
extensive commercial applications by now have a sufficiently long history of safe use. What 
was considered negligible risks already in the late 1980s (Young & Miller, 1987; NAS, 1987) 
has been proven beyond doubt to be at a level comparable to that of conventional breeding 
(Kuntz & Ricroch, 2012; DeFrancesco, 2013; Nicolia et al., 2013; Barrows et al., 2014; 
Ricroch & Kuntz, 2014; Sanchez, 2015; Castanera et al., 2016; Bartholomaeus, 2018; ICGEB, 
2018; Ricroch et al., 2018). Also, what was still considered a technology potential 16 years 
ago (Dale et al., 2002) has now translated into extensive on-farm and environmental benefits 
(Carpenter, 2010; 2011; Benbrook, 2012; Green, 2012; Klumper & Qaim, 2014; Brookes, 
2014; Brookes & Barfoot, 2017a; 2017b; Pellegrino, 2018). Also, there are signs that several 
EU countries look favourably on the commercial application of directed mutagenesis 
(Eriksson, 2018). Despite the regulatory gridlock that has persisted in the EU for the 
authorization for commercial field release for GMOs over the past 20 years (Smart et al., 2015), 
it is therefore not to be taken for granted that the products of directed mutagenesis will suffer 
the same fate even if they would be regulated as GMOs and if there should be any applications 
for authorization even in the near future. This may in fact serve to return the EU GMO 
regulations to the case-by-case implementation of the level of required risk assessment that was 
envisaged in the first GMO directive adopted in 1990. 
Nevertheless; given the far-reaching consequences the CJEU ruling may have for the 
international trade with agricultural commodities, it is essential that the EC immediately 
engages in bilateral and multilateral discussions with trading partners and within the WTO on 
how to handle the products of directed mutagenesis in a mutually beneficial way and which 
will not unjustifiably hinder international trade with these products and in particular not prevent 
access for African countries that would greatly benefit from these technologies (Wesseler et 
al., 2017). We, as publicly funded academic researchers or public officials, are available for 
policy and law makers in our respective jurisdictions to provide scientific background data in 
order to facilitate the development of this process in a transparent and evidence-based way. 
 
Acknowledgements 
This work was supported by the Swedish Foundation for Strategic Environmental Research 
(Mistra) through the Mistra Biotech public research programme. 
 
Author contributions 
DE planned and designed the work, wrote the introduction, analysis, discussion and conclusion, 
and assembled the manuscript. DK, AN, BP, HP, SS and AW contributed with their respective 
country descriptions. KP and JW contributed with analysis and parts of the discussion. KP in 
addition contributed to the introduction and wrote much of the part describing the CJEU case 
 
Disclosure 
The information and views are those of the authors as individuals and experts in the field, and 
do not necessarily represent those of the organizations where they work. 
 
Disclosure of potential conflicts of interest 
No potential conflicts of interest were disclosed. 
 
Figure and Table legends 
Figure 1. Roadmap for the regulatory classification of new breeding techniques, including 
genome edited crops, in Argentina. So far, this procedure is only available for plants and 
animals. 
Table 1. Examples of events obtained by directed mutagenesis which are in the pipeline for 
commercialization, and which regulatory authorities have declared to not be regulated as GMO. 
Table 2.  Events (non-microbial) that have been obtained by directed mutagenesis and which 
have been approved for commercialization in the respective jurisdiction. 
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